Clinical trial

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

NCT02400814

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-12-03

PhasePHASE1

Study timeline

Study start (actual)2015-12-03Date precision: day

Registry last updated2022-08-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Recurrent Non-Small Cell Lung Carcinomaunresolved

Stage IV Non-Small Cell Lung Cancerunresolved

Interventions

Anti-PD-L1 Monoclonal Antibody MPDL3280ADRUG

Stereotactic Body Radiation TherapyRADIATION

Sponsors & collaborators

Megan Daly, MDlead sponsor

National Cancer Institute (NCI)collaborator

Genentech, Inc.collaborator

Mapped research locations

SacramentoCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02400814 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.